Bibliography
- DIMASI JA, HANSEN RW, GRABOWSKI HG: The price of innovation: new estimates of drug development costs. J. Health Econ. (2003) 22(2):151-185.
- HILFIKER R: Relevance of solid-state properties for pharmaceutical products. In: Polymorphism in the Pharmaceutical Industry. Hilfiker R (Ed.), Wiley-VCH, Weinheim, Germany and John Wiley, Chichester, UK (2006):1-19.
- NEWMAN AW, BYRN SR: Solid-state analysis of the active pharmaceutical ingredient in drug products. Drug Discov. Today (2003) 8(19):898-905.
- DATTA S, GRANT DNW: Crystal structures of drugs: advances in determination, prediction and engineering. Nat. Rev. Drug Discov. (2004) 3(1):42-57.
- SHETH AR, GRANT DNW: Relationship between the structure and properties of pharmaceutical crystals. KONA (2005) 23:36-48.
- BYRN SR, PFEIFFER RR, STOWELL JG: Solid-state chemistry of drugs. (2nd edn.) (1999):574.
- CHEMBURKAR SR, BAUER J, DEMING K et al.: Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development. Org. Pro. Res. Devel. (2000) 4(5):413-417.
- BAUER J, SPANTON S, HENRY R et al.: Ritonavir: an extraordinary example of conformational polymorphism. Pharm. Res. (2001) 18(6):859-866.
- DU Q, PING QN: Investigation of buspirone hydrochloride polymorphs. Zhongguo Yaoke Daxue Xuebao (2000) 31(2):102-104.
- SHEIKHZADEH M, ROHANI S, JUTAN A, MANIFAR T, MURTHY K, HORNE S: Solid-state characterization of buspirone hydrochloride polymorphs. Pharm. Res. (2006) 23(5):1043-1050.
- CHILDS SL, CHYALL LJ, DUNLAP JT, COATES DA, STAHLY BC, STAHLY GP: A metastable polymorph of metformin hydrochloride: isolation and characterization using capillary crystallisation and thermal microscopy techniques. Crystal Growth Des. (2004) 4(3):441-449.
- PETERSON ML, MORISSETTE SL, MCNULTY C et al.: Iterative high-throughput polymorphism studies on acetaminophen and an experimentally derived structure for form III. J. Am. Chem. Soc. (2002) 124(37):10958-10959.
- IVANISEVIC I, BUGAY DE, BATES S: On pattern matching of X-ray powder diffraction data. J. Phys. Chem. B Condens. Matter Mater. Surf. Interfaces Biophys. (2005) 109(16):7781-7787.
- CHEN X, BATES S, MORRIS KR: Quantifying amorphous content of lactose using parallel beam X-ray powder diffraction and whole pattern fitting. J. Pharm. Biomed. Anal. (2001) 26(1):63-72.
- DOCHERTY R, CLYDESDALE G, ROBERTS KJ, BENNEMA P: Application of Bravais-Friedel-Donnay-Harker, attachment energy and ising-models to predicting and understanding the morphology of molecular-crystals. J. Phys. D-Appl. Phys. (1991) 24(2):89-99.
- DONNAY JD, HARKER D: A new law of crystal morphology extending the law of bravais. Am. Mineral. (1937) 22:446-467.
- FLORENCE AJ, BAUMGARTNER B, WESTON C et al.: Indexing powder patterns in physical form screening: instrumentation and data quality. J. Pharm. Sci. (2003) 92(9):1930-1938.
- SPERANDEO NR, KARLSSON A, CUFFINI S, PAGOLA S, STEPHENS PW: The crystal structure and physicochemical characteristics of 2-hydroxy-N-[3(5)-pyrazolyl]-1,4-naphthoquinone-4-imine, a new antitrypanosomal compound. AAPS PharmSciTech (2005) 6(4):E655-E663.
- STAHLY GP, BATES S, ANDRES MC, COWANS BA: Discovery of a new polymorph of dehydroepiandrosterone (Prasterone) and solution of its crystal structure from X-ray powder diffraction data. Crystal Growth Des. (2006) 6(4):925-932.
- BURGER A, RAMBERGER R: On the polymorphism of pharmaceuticals and other molecular crystals. I. Theory and thermodynamic rules. Mikrochim. Acta (1979) 2:259-271.
- CHILMONCZYK Z, LES A, WOZNIAKOWSKA A, CYBULSKI J, KOZIOL AE, GDANIEC M: Buspirone analogues as ligands of the 5-HT1A receptor. 1. The molecular structure of buspirone and its two analogues. J. Med Chem. (1995) 38(10):1701-1710.
- MCNAMARA P, CHILDS S, GIODANO J et al.: Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm. Res. (2006) 23(8):1888-1897.
- SHETH AR, BATES S, MULLER FX, GRANT DJ: Local structure in amorphous phases of piroxicam from powder X-ray Diffractometry Crystal Growth Des. (2005) 5(2):571-578.
- BAERLOCHER C, MCCUSKER LB: Structure determination from powder diffraction data. Zeitschrift für Kristallographie (2004) 219(12):782-782.
- BERGMANN J, LE BAIL A, SHIRLEY R, ZLOKAZOV V: Renewed interest in powder diffraction data indexing. Zeitschrift für Kristallographie (2004) 219(12):783-790.
- SHANKLAND K, MARKVARDSEN A, DAVID WI: Powder diffraction based structural studies of pharmaceuticals. Zeitschrift für Kristallographie (2004) 219(12):857-865.
- CHILDS SL, CHYALL LJ, DUNLAP JT, SMOLENSKAYA VN, STAHLY BC, STAHLY GP: Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. J. Am. Chem. Soc. (2004) 126(41):13335-13342.
- TRASK AV, MOTHERWELL WD, JONES W: Physical stability enhancement of theophylline via cocrystallization. Int. J. Pharm. (2006) 320(1):114-123.
- LEE J: Drug nano- and microparticles processed into solid dosage forms: physical properties. J. Pharm. Sci. (2003) 92(10):2057-2068.
Patents
- ALLEN & HANBURYS LTD: US4128658 (1978).
- GLAXO GROUP LTD: US4521431 (1985).
- BRISTOL-MYERS CO.: US3489752 (1970).
- BRISTOL-MYERS CO.: US4504657 (1985).
- A/S FERROSAN: US4007196 (1977).
- BEECHAM GROUP: US4721723 (1988).
- MEAD JOHNSON & CO.: US4182763 (1980).
- BRISTOL-MYERS CO.: US5015646 (1991).
- SSCI, INC.: PURDUE RESEARCH FOUNDATION: US6642060 (2003).
- SSCI, INC: PURDUE RESEARCH FOUNDATION: US6750064 (2004).
- SSCI, INC: PURDUE RESEARCH FOUNDATION: US7041169 (2006).
Websites
- http://www.aegis.org/news/pr/1998/PR980710.htmlPR Newswire; Tuesday July 28, 1998.
- http://www.zinsserna.com/crissy.htmCrissy® -Automation Platform for Salt Prescreening and Polymorph Screening Studies (2006).
- http://www.chemspeedtechnologies.com/specialty.htmlChemspeedtechnologies (2006).
- http://www.tessella.co.uk/services/discipline/high_throughput_technology.htmTessella. High throughput technology (2006).
- http://www.symyx.com/page.php?page=124.Symyx. Preformulations workflow (2006).
- http://www.cfsan.fda.gov/~rdb/opa-gras.htmlFDA. Summary of all GRAS notices (2006).
- http://www.cfsan.fda.gov/~dms/grasguid.htmlFDA. Frequently asked questions about GRAS (2006).
- http://www.avantium.com/corporate/services/introduction/rational-approach.htmAvantium (2006).
- http://www.pharmorphix.com/index.php?num=120Pharmorphix. Polymorph investigation (2004).
- http://www.solvias.com/english/products-and-services/polymorphismsalts/index.htmlSolvias. Polymorphism and salts (2006).
- http://www.pharmaterials.co.uk/solid-state-chemistry.php.php?PHPSESSID=f3beb9c680dd2df4b4bd6c4858460efa Pharmaterials. Solid-atate chemistry: introduction (2005).
- http://www.icdd.com/ppxrd/04/reginfo/Franck%20Leveiller%20Abstract.pdf#search=%22x-ray%20diffraction%20applied%20to%20drug%20development%22 X-ray diffraction applied to drug development – an overview (2004).
- http://www.drugdeliverytech.com/cgi-bin/articles.cgi?idArticle=153Dendrimers & dendrons: facets of pharmaceutical nanotechnology (2006).
- http://www.the-infoshop.com/study/fd29054_nanotechnology_toc.htmlNanotechnology in healthcare to 2009 (2005).